Natco Pharma is currently trading at Rs. 965.00, up by 8.60 points or 0.90% from its previous closing of Rs. 956.40 on the BSE.

The scrip opened at Rs. 955.05 and has touched a high and low of Rs. 992.00 and Rs. 955.05 respectively. So far 196763 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1059.60 on 24-Jul-2025 and a 52 week low of Rs. 660.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 998.40 and Rs. 820.35 respectively. The current market cap of the company is Rs. 17,276.94 crore.

The promoters holding in the company stood at 49.48%, while Institutions and Non-Institutions held 20.54% and 29.97% respectively.

Natco Pharma, along with its partner Breckenridge Pharmaceutical, has launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene in the U.S. market. Pomalidomide capsules, a thalidomide analogue, is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 

It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics.

Pomalidomide Capsules, 1mg, 2mg, 3mg and 4mg, had estimated sales of $3.2 billion in the U.S. for 12 months ending September 2025 as per industry sales data. 

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).